Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.
about
Unmet needs of patients with narcolepsy: perspectives on emerging treatment optionsDirect nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?Role of oxytocin signaling in the regulation of body weight.Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdalaMethodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations.Intranasal treatment of central nervous system dysfunction in humans.Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery.Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humansOxytocin biases men but not women to restore social connections with individuals who socially exclude themNew developments in the management of narcolepsy.Intranasal delivery of stem cells to the brain.The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.Nanoneurotherapeutics approach intended for direct nose to brain delivery.Intranasal delivery: circumventing the iron curtain to treat neurological disorders.Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery.Learning and memory performance following acute intranasal insulin administration in abstinent smokers.Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting.Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.
P2860
Q26827736-F94DFC36-3D09-4E12-B496-AC7A0C816A80Q34339313-8F59FC51-79B9-4CBE-A10F-8349B054341EQ34383339-04655EA1-F4BF-47DC-9A84-85D4FD5E2B3AQ34425122-1EAFA7C5-7803-4233-BED6-57FC66C525B6Q35183155-E2C4761C-BC57-4E43-8214-C19227D8BAEBQ35847142-89070E44-B3A8-461F-8953-49EF42D5EA2FQ35892698-1607D1C3-BC13-43FA-9DBC-12DB12BAA64FQ36461829-382D4715-EB6F-4384-88A3-77B993656E82Q37142166-1F0C26B7-EE6A-4DA7-97CC-BE99F5CF9A6FQ37202528-C9E735E7-7200-4C88-BDA6-BAB7CBEC6951Q37369702-5392E9E4-4AD1-488F-A038-C94D2E599D1BQ37581522-D688099D-836D-4E95-9B92-B9C299CB8E2BQ37691690-A3F362B4-657C-4F88-83EC-AF03559A5242Q37854671-B68189D8-029B-4C68-890A-9362A1E49EB0Q38236698-48951132-282B-49C3-ABA7-F2F585DD80C5Q38522125-A6C5471D-5360-4371-927C-ED0643B92EFDQ38553213-1F231C19-0050-4AB0-B671-D4644C3C524DQ47585305-E958357C-8989-4856-B4C6-8DA8D9489D13Q47715583-9FEA891C-1DE5-4BDA-AFCD-AF734474C172Q47893114-6CB3D0BE-6E90-4A1C-B2E5-1B543C32A53BQ48117495-24AC5996-0D51-4F7A-A776-0F1FC1A327BD
P2860
Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Novel vasoconstrictor formulat ...... to the central nervous system.
@en
Novel vasoconstrictor formulat ...... to the central nervous system.
@nl
type
label
Novel vasoconstrictor formulat ...... to the central nervous system.
@en
Novel vasoconstrictor formulat ...... to the central nervous system.
@nl
prefLabel
Novel vasoconstrictor formulat ...... to the central nervous system.
@en
Novel vasoconstrictor formulat ...... to the central nervous system.
@nl
P2093
P356
P1476
Novel vasoconstrictor formulat ...... to the central nervous system.
@en
P2093
Leah R Hanson
Shyeilla V Dhuria
William H Frey
P304
P356
10.1124/JPET.108.145565
P407
P577
2008-10-22T00:00:00Z